With direct letters, regulatory comments and other activities, Vizient strives to form constructive relationships with lawmakers, regulatory agencies and administration officials, to provide a unified voice on issues that have a direct impact on our members.
2021 Advocacy
May 3 - Vizient endorses the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act
Vizient, Inc.
April 29 - Vizient endorses the Opioid Workforce Act of 2021Vizient, Inc.
April 16 – Vizient comments to HHS on Request for Information (RFI) on Termination of the FDA’s Unapproved Drugs InitiativeVizient, Inc.
April 9 - Vizient encourages support for providers in Congressional infrastructure legislationVizient, Inc.
March 31 - Vizient supports $485 million for Children's Hospital Graduate Medical Education (CHGME) for FY2022Vizient, Inc.
March 25: Vizient Requests Additional Information from CMS and CMMI Regarding the Medicare Shared Savings Program and Direct Contracting Model OptionsVizient, Inc.
March 25 – Vizient endorses the Strengthening Rural Health Clinics ActVizient, Inc.
March 24 – Vizient joins other health care stakeholders in support of the Resident Physician Shortage Reduction ActVizient, Inc.
March 24 – Vizient endorses the Resident Physician Shortage Reduction Act of 2021Vizient, Inc.
March 22 – Vizient joins other health care stakeholders in letter to FDA regarding the payer-mandated distribution models and the Drug Supply Chain Security Act (DSCSA)Vizient, Inc.
March 12 – Vizient urges Congressional leadership to extend the Medicare sequester moratorium and prevent the projected Medicare PAYGO spending cutVizient, Inc.
February 25 - Vizient encourages Senate leadership to provide additional funding for health care providers in the current budget reconciliation packageVizient, Inc.
February 12 - Vizient submits additional policy requests to Congress on COVID-19 reliefVizient, Inc.
February 3 – Vizient joins other health care stakeholders in urging a delay of the Medicare SequesterVizient, Inc.
February 2 – Vizient supports the Temporary Reciprocity to Ensure Access to Treatment (TREAT) ActVizient, Inc.
January 29 - Vizient Endorses Legislation to Extend the Moratorium on the Medicare SequesterVizient, Inc.
January 27 - Vizient applauds Congressional leaders for supporting physician workforceVizient, Inc.
January 25 - Vizient Urges CMS to Withdraw Harmful Most Favored Nation RuleVizient, Inc.
January 4 - Vizient comments to CMS on Reducing Provider and Patient Burden by Improving Prior Authorization Processes and Promoting Patients’ Electronic Access to Health InformationVizient, Inc.
2020 Advocacy
December 28 - Vizient comments to HHS on Request for Information (RFI) on Regulatory Relief to Support Economic Recovery
Vizient, Inc.
Dec. 22 - Vizient letter to the U.S. Trade Representative urging a continuation of Sec. 301 tariff exclusionsVizient, Inc.
Dec. 22 - Vizient comments to the Department of Commerce on policies to strengthen the U.S. public health industrial base.Vizient, Inc.
December 14 - Vizient endorsed coalition letter in support of the PASTEUR ActVizient, Inc.
December 10 – Vizient urges CMS to delay the start of Most Favored Nation (MFN) ModelVizient, Inc.
December 4 – Vizient comments to CMS on Public Health Focused Essential Medicines, MCM and Their Critical Inputs ListVizient, Inc.
November 18 - Vizient submits additional policy requests to Congress on COVID-19 reliefVizient, Inc.
November 12 - Vizient Urges Congress to Extend Sequestration MoratoriumVizient, Inc.
November 2 - Vizient comments to CMS on Third Interim Final Rule on Policy and Regulatory Revisions in Response to the COVID-19 Public Health EmergencyVizient, Inc.
October 14 - Vizient comments to NIOSH on CDC’s National Elastomeric Half Mask Respirator (EHMR) Strategy for Use in Healthcare SettingsVizient, Inc.
Oct. 13 - Vizient letter to HHS Regarding Changes to Provider Relief Fund GuidelinesVizient Office of Public Policy and Government Relations
October 5 - Vizient comments on the CY 2021 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) proposed ruleVizient, Inc.
October 5 - Vizient comments on the CY 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed ruleVizient, Inc.
August 31 – Vizient comments to FDA on Approved Drug Products With Therapeutic Equivalence Evaluations (the “Orange Book”)Vizient, Inc.
August 24 - Vizient letter of support for the Safe Drugs ActVizient, Inc.
August 5 - Vizient signs coalition letter in support of finalizing Stark and Anti-Kickback Statute reformsVizient, Inc.
July 30 - Vizient endorsed coalition letter urging the exclusion of damaging surprise billing proposals in COVID-19 relief legislationVizient, Inc.
July 29 - Senate Finance Committee Testimony of Cathy DenningVizient Inc.
July 21 - Vizient submits policy requests to Congress on additional COVID-19 reliefVizient, Inc.
July 14 - Vizient urges Treasury and IRS to extend deadlines for tax-exempt hospitals to complete their Community Health Needs Assessment and implementation strategyVizient, Inc.
July 10 – Vizient endorsed coalition letter in support of enhanced Medicaid FMAP and rescinding the Medicaid Fiscal Accountability Regulation in supplemental coronavirus response legislationVizient, Inc.
July 10 - Vizient comments on the FY 2021 Inpatient Prospective Payment System proposed ruleVizient, Inc.
July 9 – Vizient endorsed coalition letter urging the inclusion of The Resident Physician Shortage Reduction Act in supplemental coronavirus response legislationVizient, Inc.
July 7 – Vizient submits policy requests to Congress on expansion of telehealth flexibilitiesVizient, Inc.
July 7 – Vizient comments to CMS on Policy and Regulatory Revisions in Response to the COVID-19 Public Health EmergencyVizient, Inc.
June 26 – Vizient comments to the USPTO regarding Patent Trial and Appeal Board Rules of Practice for Instituting on All Challenged Patent Claims and All Grounds and Eliminating the Presumption at Institution Favoring Petitioner as to Testimonial EvidenceVizient, Inc.
June 22 – Vizient submits comments to the Department of the Treasury and Federal Reserve Board on Main Street Lending Program Nonprofit LoansVizient, Inc.
May 11 – Vizient submits comments to DEA on Aggregate Production Quota Adjustments in Response to the Coronavirus Disease 2019 Public Health EmergencyVizient, Inc.
May 7 - Vizient joins hospital provider groups in urging support for liability protections for front-line providersVizient, Inc.
April 24 – Vizient submits comments to CMS on the Comprehensive Care for Joint Replacement ModelVizient, Inc.
April 23 - Vizient endorsed joint hospital letter to HHS/CMS re: Accelerated and Advanced PaymentsVizient, Inc.
April 16 - Vizient submits policy requests to Congress on COVID-19 reliefVizient, Inc.
March 23 – Vizient recommendations to the White House Coronavirus Task Force and FDA on Access to Chloroquine and HydroxychloroquineVizient, Inc.
March 16 – Vizient recommendations to the White House Coronavirus Task Force and CMS on Supply Strategies for Personal Protective Equipment and PharmaceuticalsVizient, Inc.
March 12 – Vizient endorsed coalition letter in support of funding for Children’s Hospitals Graduate Medical Education (CHGME) for FY 2021.Vizient, Inc.
March 6 – Vizient comments on Importation of Prescription DrugsVizient, Inc.
March 6 – Vizient comments to CMS on the Hospital Survey for Specified Covered Outpatient DrugsVizient, Inc.
January 31 – Vizient Comments to CMS on Medicaid Fiscal Accountability RegulationVizient, Inc.
January 27 – Vizient Comments to FDA on Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin ProductsVizient, Inc.
2019 Advocacy
Nov. 29 – Vizient’s response to the House Ways and Means Committee’s Rural and Underserved Health Care Task Force RFI
Vizient, Inc.
November 29 – Vizient comments on Hospital Survey for Specified Covered Outpatient DrugsVizient, Inc.
November 21 - Vizient Supports Opioid Workforce Act of 2019Vizient, Inc.
October 15 – Vizient comments on the DEA Proposed Aggregate Production Quotas for Schedule I and II Controlled SubstancesVizient, Inc.
September 27 - Vizient comments on the CY 2020 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed ruleVizient, Inc.
September 27 - Vizient comments on the CY 2020 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) proposed ruleVizient, Inc.
June 24 - Vizient comments on the FY 2020 Inpatient Prospective Payment System proposed ruleVizient, Inc.
May 31 - Vizient comments to CMS on promoting interoperability and increasing access to electronic health informationVizient, Inc.
May 30 - Vizient letter of support for the Protecting Local Access to Care for Everyone (PLACE) ActVizient, Inc.
May 10 - Vizient letter of support for the Affordable Prescriptions for Patients ActVizient, Inc.
May 7 - Vizient comments to FDA on the nonproprietary naming of biological productsVizient, Inc.
April 10 - Vizient endorsed coalition letter to members of Congress urging their support for the Resident Physician Shortage Reduction ActVizient, Inc.
March 29 - Vizient comments to CMS on potential updates to the Hospital Star Ratings methodologyVizient, Inc.
March 18 - Vizient comments to the FDA on updated draft guidance regarding the content of premarket submissions for management of cybersecurity in medical devicesVizient, Inc.
March 14 - Vizient letter of support for the FAST Generics Act of 2019Vizient, Inc.
March 14 - Vizient letter of support for the Biologic Patent Transparency ActVizient, Inc.
Feb. 19 - Vizient endorsed hospital coalition letter to Congress urging a delay in pending Medicaid DSH payment cutsVizient, Inc.
Feb. 15 - Vizient letter to the Senate cosponsors in support of the ACE Kids ActVizient, Inc.
Feb. 15 - Vizient letter to the House cosponsors in support of the ACE Kids ActVizient, Inc.
Feb. 8 - Vizient letter of support for the Resident Physician Shortage Reduction Act of 2019Vizient, Inc.
Feb. 5 - Vizient letter of support for the CREATES ActVizient, Inc.
Feb. 5 - Vizient endorsed coalition letter to the Senate in support of the CREATES Act.Vizient, Inc.
2018 Advocacy
Dec. 21 - Vizient comments to CMS on the International Pricing Index Model advanced notice of proposed rulemaking
Vizient, Inc.
Nov. 19 – Vizient-endorsed coalition letter to the Senate in support of the Overdose Prevention and Patient Safety ActVizient, Inc.
Nov. 19 - Vizient comments to CMS on the proposed rule to revise certain Medicare conditions of participation for providers and conditions for coverageVizient, Inc.
Sept. 24 – Vizient response to CMS request for information regarding a Competitive Acquisition Program for Medicare Part B drugs and biologics.Vizient, Inc.
Sept. 24 – Vizient comments on the FY 2019 outpatient prospective payment system proposed rule.Vizient, Inc.
Sept. 21 - Vizient comments to the FDA on facilitating competition and innovation in the biological products marketplaceVizient, Inc.
Sept. 19 - Vizient-endorsed coalition letter supporting inclusion of coordinated care provisions in final opioid agreementVizient, Inc.
Sept. 19 - Vizient Comments to DEA on Proposed Controlled Substance Quotas for 2019Vizient, Inc.
Sept. 10 - Vizient comments on the CY 2019 Physician Fee Schedule and Quality Payment Program proposed ruleVizient, Inc.
Aug. 31 - Vizient comments to CMS on the CY 2019 Home Health proposed ruleVizient, Inc.
August 23 - Vizient-endorsed coalition letter urging the FDA to finalize guidance critical to lower drug pricesVizient, Inc.
July 16 - Vizient comments on HHS request for information on ways to lower drug prices and reduce out-of-pocket costs for consumersVizient Inc.
June 12 - Vizient letter of support for the SERV Communities Act.Vizient, Inc.
June 25 - Vizient comments on the FY 2019 Inpatient Prospective Payment System proposed ruleVizient, Inc.
June 7 - Vizient-endorsed coalition letter to the Senate Judiciary Committee in support of the CREATES Act.Vizient, Inc.
May 30, 2018 - Vizient feedback on the CMS methodology for the Overall Hospital Quality Star RatingVizient Inc.
May 30 - Vizient comments to the FDA regarding its Medical Device Safety Action Plan.Vizient, Inc.
May 22 - Vizient comments to the IRS in support of further agency guidance around hospital community benefit.Vizient, Inc.
May 15 - Vizient-endorsed hospital letter to House Energy and Commerce Committee in support of modifying the IMD exclusion.Vizient, Inc.
May 11 – Vizient comment letter to USTR on proposed policies and tariffs against Chinese productsVizient, Inc.
May 3 - Vizient Comments to DEA on Controlled Substance QuotasVizient, Inc.
March 29 - Vizient letter to USP providing feedback on biosimilar namingVizient, Inc.
March 26 - Vizient letter of support for H.R. 5385, the Children's Hospital GME Support Reauthorization Act.Vizient, Inc.
March 26 - Vizient letter of support for S. 2597, the Children's Hospital GME Support Reauthorization Act.Vizient, Inc.
Feb. 6 - Vizient endorsed coalition letter urging passage of the CREATES Act.Vizient, Inc.
Jan. 17 - Vizient endorsed hospital coalition letter to the House supporting delay of Medicaid DSH cuts and extension of Medicare Dependent Hospital and Low Volume Adjustment programs in continuing resolution.Vizient, Inc.
Jan. 17 - Vizient endorsed hospital coalition letter to the Senate supporting delay of Medicaid DSH cuts and extension of Medicare Dependent Hospital and Low Volume Adjustment programs in continuing resolution.Vizient
Connect with Vizient to help you solve health care’s biggest challenges